In support of this, patients carrying tumors with mutant p53 proteins display higher oncogenic potential, poor prognosis, poor response to chemotherapy and accelerated tumor recurrence compared to patients with p53 null tumors (13, 14). This evidence concerns the gene TP53 and neoplasm.